FIELD: biochemistry.
SUBSTANCE: present invention relates to biochemistry, particularly to using a composition containing an agent, inhibiting MASP-2, in an amount effective for inhibiting or preventing formation of deposits in vascular system of a patient, for preparing a drug for treating said patient suffering or subject to risk of developing a complement-mediated disorder of blood coagulation, such as disseminated intravascular blood coagulation (DIC). Present invention also discloses use of said composition in preparing a drug for treating or preventing an infection of meningococcus Neisseria meningitidis in patient. Present invention also discloses a method of treating complement-mediated disorder and method of treating or preventing an infection of meningococcus Neisseria meningitidis in patient.
EFFECT: present invention discloses new applications of an agent which inhibits MASP-2, and widens range of products for treating DIC and infection of Neisseria meningitidis.
39 cl, 40 dwg, 7 tbl, 40 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2662563C2 |
| METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2743409C2 |
| COMPOSITIONS AND METHODS OF INHIBITING MASP-1, MASP-2 AND/OR MASP-3 FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | 2013 |
|
RU2655299C2 |
| COMPOSITIONS AND METHODS OF INHIBITING MASP-1, AND/OR MASP-2, AND/OR MASP-3 FOR TREATING VARIOUS DISEASES AND DISORDERS | 2013 |
|
RU2709351C2 |
| COMPOSITIONS FOR INHIBITION OF MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2636038C2 |
| METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2014 |
|
RU2718850C2 |
| COMPOSITIONS FOR INHIBITING MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2017 |
|
RU2725958C2 |
| METHOD FOR DETERMINING ACTIVITY OF MANNAN-BINDING LECTIN-ASSOCIATED SERINE PROTEASES IN A FIBRINOGEN COAGULATION TEST | 2019 |
|
RU2739113C1 |
| DETERMINING THE ACTIVITY OF THE CLASSICAL PATHWAY OF THE COMPLEMENT SYSTEM IN A FIBRINOGEN COAGULATION TEST | 2019 |
|
RU2707568C1 |
| METHOD FOR DETERMINING THE INHIBITORY POTENTIAL OF BLOOD FOR PREDICTING UNCONTROLLED ACTIVATION OF COMPLEMENT SYSTEM IN COVID-19 | 2023 |
|
RU2814496C1 |
